CytomX Therapeutics (CTMX) Current Leases (2019 - 2026)

CytomX Therapeutics' Current Leases history runs 8 years deep, the most recent figure standing at $2.9 million for Q1 2026.

• Quarterly Current Leases fell 46.04% year-over-year to $2.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $2.9 million (down 46.04% YoY) and the FY2025 annual result came in at $4.2 million, down 17.59% from the prior year.
• Current Leases was $2.9 million for Q1 2026 at CytomX Therapeutics, down from $4.2 million in the prior quarter.
• Across five years, Current Leases topped out at $5.6 million in Q3 2025 and bottomed at $2.9 million in Q1 2026.
• A 5-year average of $4.5 million and a median of $4.5 million in 2023 frame the typical range for Current Leases.
• Annual changes were most pronounced in 2022 — Current Leases rose 12.82% — and 2026, when it slumped 46.04%.
• CytomX Therapeutics' Current Leases stood at $4.1 million in 2022, then grew by 12.42% to $4.6 million in 2023, then rose by 12.12% to $5.1 million in 2024, then declined by 17.59% to $4.2 million in 2025, then tumbled by 32.64% to $2.9 million in 2026.
• Business Quant data shows CTMX's Current Leases at $2.9 million in Q1 2026, $4.2 million in Q4 2025, and $5.6 million in Q3 2025.